
Atrion Corporation ATRI
Annual report 2023
added 02-29-2024
Atrion Corporation Accounts Receivables 2011-2026 | ATRI
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Atrion Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 K | 24 K | 21 M | 16.4 M | 18.9 M | 17 M | 17.1 M | 17.2 M | 16.6 M | 17 M | 14.2 M | 13.1 M | 11.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21 M | 23 K | 13.8 M |
Quarterly Accounts Receivables Atrion Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.3 M | 23.7 M | 19.4 M | - | 22 M | 27.5 M | 24.2 M | 21 M | 25.2 M | 22.7 M | 20.2 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 18.9 M | 18.9 M | 18.9 M | 21.2 M | 17 M | 17 M | 17 M | 17 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 17 M | 17 M | 17 M | 17 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.5 M | 11.2 M | 17.3 M |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
1.54 B | $ 20.1 | 1.85 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
7.24 M | $ 8.57 | 2.15 % | $ 173 M | ||
|
AtriCure
ATRC
|
60.3 M | $ 36.9 | -0.14 % | $ 1.73 B | ||
|
electroCore
ECOR
|
717 K | $ 6.6 | -7.04 % | $ 36.4 K | ||
|
Haemonetics Corporation
HAE
|
203 M | $ 66.55 | 0.88 % | $ 3.35 B | ||
|
AngioDynamics
ANGO
|
42.9 M | $ 10.3 | 3.21 % | $ 421 M | ||
|
ICU Medical
ICUI
|
183 M | $ 148.85 | -0.79 % | $ 3.63 B | ||
|
InfuSystem Holdings
INFU
|
16.9 M | $ 8.27 | 2.73 % | $ 171 M | ||
|
The Cooper Companies
COO
|
829 M | $ 81.34 | 1.21 % | $ 16.2 B | ||
|
Harvard Bioscience
HBIO
|
16.1 M | $ 0.5 | -6.73 % | $ 21.2 M | ||
|
Glaukos Corporation
GKOS
|
39.8 M | $ 119.29 | 0.28 % | $ 5.78 B | ||
|
Isoray
ISR
|
116 K | - | 0.03 % | $ 108 M | ||
|
Repro Med Systems
KRMD
|
4.05 M | $ 5.39 | -1.1 % | $ 246 M | ||
|
iRhythm Technologies
IRTC
|
79.9 M | $ 154.21 | 3.5 % | $ 4.81 B | ||
|
LeMaitre Vascular
LMAT
|
30.1 M | $ 84.97 | 1.32 % | $ 1.91 B | ||
|
Masimo Corporation
MASI
|
141 M | $ 137.49 | 0.91 % | $ 7.33 B | ||
|
Intuitive Surgical
ISRG
|
1.23 B | $ 505.17 | -0.47 % | $ 179 B | ||
|
Merit Medical Systems
MMSI
|
190 M | $ 80.93 | 0.85 % | $ 4.71 B | ||
|
Microbot Medical
MBOT
|
159 K | $ 1.81 | -2.96 % | $ 18.5 M | ||
|
Nephros
NEPH
|
1.5 M | $ 4.35 | -0.91 % | $ 45.2 M | ||
|
Milestone Scientific
MLSS
|
475 K | $ 0.29 | -2.67 % | $ 23.1 M | ||
|
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
363 M | $ 23.4 | 0.13 % | $ 4.03 B | ||
|
OraSure Technologies
OSUR
|
23.8 M | $ 2.78 | -0.54 % | $ 207 M | ||
|
Pro-Dex
PDEX
|
16.4 M | $ 38.77 | -1.61 % | $ 127 M | ||
|
Predictive Oncology
POAI
|
746 K | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
61 K | $ 13.76 | 0.99 % | $ 661 M | ||
|
Becton, Dickinson and Company
BDX
|
2.99 B | $ 203.2 | 1.05 % | $ 58.5 B | ||
|
Repligen Corporation
RGEN
|
124 M | $ 150.44 | -3.8 % | $ 8.38 M | ||
|
ResMed
RMD
|
576 M | $ 256.15 | -0.57 % | $ 37.4 B | ||
|
STERIS plc
STE
|
1.04 B | $ 261.9 | 0.02 % | $ 25.8 B | ||
|
BioLife Solutions
BLFS
|
9.17 M | $ 21.91 | -2.97 % | $ 1.01 B | ||
|
Stereotaxis
STXS
|
3.82 M | $ 2.21 | -5.36 % | $ 178 M | ||
|
Retractable Technologies
RVP
|
7.79 M | $ 0.7 | -1.03 % | $ 21 M | ||
|
STAAR Surgical Company
STAA
|
77.9 M | $ 18.9 | -0.24 % | $ 928 M | ||
|
Utah Medical Products
UTMD
|
3.39 M | $ 61.21 | -0.71 % | $ 222 M | ||
|
Teleflex Incorporated
TFX
|
459 M | $ 104.44 | -0.96 % | $ 4.89 B | ||
|
West Pharmaceutical Services
WST
|
552 M | $ 231.57 | -0.4 % | $ 16.9 B |